Mickey Kertesz, KidsandArtOrg via YouTube

Soft­Bank's newest, $165M biotech in­vest­ment looks for in­fec­tious traces in the blood

Soft­Bank has found its newest biotech in­vest­ment.

The Japan­ese bank has in­vest­ed $165 mil­lion in­to Kar­ius, a com­pa­ny that us­es blood tests to di­ag­nose in­fec­tious dis­eases, as part of its new Vi­sion Fund 2. The full scope of the new fund has yet to be an­nounced, but the first and new­ly-be­lea­guered Vi­sion Fund poured $100 bil­lion in­to tech­nol­o­gy com­pa­nies, in­clud­ing the biotechs Vir Biotech­nol­o­gy and Roivant and the se­quenc­ing com­pa­ny 10x Ge­nomics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.